key: cord-0772558-ofmrcot2
authors: Sica, Antonello; Casale, Danilo; Rossi, Giovanni; Casale, Beniamino; Ciccozzi, Massimo; Fasano, Morena; Ciotti, Marco; Sagnelli, Evangelista; Papa, Alfonso; Sagnelli, Caterina
title: The impact of the SARS‐CoV‐2 infection, with special reference to the haematological setting
date: 2020-06-19
journal: J Med Virol
DOI: 10.1002/jmv.26197
sha: 11b13f6740a8173aa864a3519aa0d527ce8a98c1
doc_id: 772558
cord_uid: ofmrcot2

SARS‐CoV‐2 is a disease known from a few months, caused by a recently arisen virus and, consequently, it is little known. The disease has a benign course in most infected subjects (children and young adults), is often symptomatic in adults over the age of 50 and often serious and life threatening in people with comorbidities and the elderly. The few data published on COVID‐19 in the blood‐oncology field report a serious clinical presentation, a serious course of the disease and a high mortality rate, as has also been reported for other cancer contexts. The current strategy for treating patients with SARS‐CoV‐2 includes antivirals that are effective against other viral infections and drugs that can moderate the cytokine storm. There is no specific vaccine and consequently all possible precautions must be taken to prevent SARS‐CoV‐2 infection in the areas of oncology, onco‐hematology, and bone marrow transplantation. In this reviewer's article, we report the information currently available on SARS‐CoV‐2 infection to help young doctors and hematologists to successfully manage patients with COVID‐19. This article is protected by copyright. All rights reserved.

In the first stages of the disease, the instrumental diagnosis in COVID-19 patients includes chest x-ray examination at the patient's bed, mainly to avoid bacterial superinfection, and the lung ultrasound examination (US). In some cases, due to organizational difficulties or sterilization protocols [34, 35] , chest radiographs may not be performed at the patient's bed. The use of High Resolution Computed Tomography (HRCT) is always indicated in clinical conditions of medium or severe gravity, in cases of clinical worsening and when the nasopharyngeal swab for the search of the viral RNA shows negative result in contrast with the clinical findings suggesting COVID 19. In the latter case, the sensitivity of HRCT is considered higher than that of the swab to detect viral RNA [36] . HRCT is particularly useful to assess the presence and the degree of ARDS and the degree of the alveolar recruitment after postural or pulmonary ventilation.

A wide use of HRCT is recommended for an early diagnosis and monitoring of lung disease, for optimizing the type and parameters of ventilation, and for highlight abdominal complications.

Doppler and Power Doppler ultrasonography have been widely used for decades to assess renal vasculature as predictor of multiorgan failure in patient with acute lung injury or in the setting of ARDS, where a massive involvement of the systemic vasculature is expected. In COVID-19 patients renal ultrasonography is performed with the aim of integrating pulmonary vasculature evaluation performed with HRCT, or in case of impossibility to move patient into the CT suite.

Pulmonary ultrasound examination in patients with concomitant chronic obstructive pulmonary disease and/or "aged pulmonary parenchyma" has limited usefulness because it requires time and is of almost zero diagnostic value.

CT is a gold standard for the evaluation of abdominal complications. This article is protected by copyright. All rights reserved.

The myocardium, generally less affected than the lung due to its lower expressiveness of ACE2 receptors, is usually evaluated with US to exclude concomitant pathologies.

However, in selected patients with a significant involvement of myocardium and in those with concomitant cardiovascular disease catheter angiography and or magnetic resonance imaging should be proposed [37, 38] .

Overall, the wide use of diagnostic imaging is useful for a careful evaluation of the pathologies of COVID-19 patients, for identifying their early stages, for therapeutic monitoring and to get information useful to prevent some side effect of drugs.

Covid-19 positive patients are at risk for respiratory complications that require either assisted ventilation or respiratory assistance through intubation or the packaging of a tracheostomy. For such serious patients is necessary to ensure a long-lasting, efficient and safe venous access and the Peripherally Inserted Central Catheter (PICC) responds to the all the organizational and management requirements. PICC placement in Covid-19 patients should be performed at confirmed diagnosis, in the post-acute phase of the illness and after primary stabilization. The positioning of the PICC must be done by a dedicated team of experts, because the success of the system must be guaranteed quickly, and in any case within 24 hours of the request, with appropriate protection measures and respecting all the principles of sterility. For this purpose, the use of an all-inclusive kit for the installation and management of the device is suggested.

The Infusion Nursing Society (INS 2016) guidelines recommend the use of standardized and certified methods of tip location and intraprocedural tip navigation, the verification and confirmation of the correct positioning of the tip of catheter during the implant, which avoids a chest X-ray to control the position of the tip of the catheter, thus This article is protected by copyright. All rights reserved.

preventing further exposure of patients to infectious and/or thrombotic risk and unnecessary contagion risk for the healthcare personnel.

In patients with a helmet or mask for ventilation or who may need this respiratory supports in the near future, the PICC finds its full use because ventilation will always be guaranteed because the catheter insertion site is in the middle third of the arm, away from the helmet or ventilation mask, and because there is no risk of its kinking, which is possible in cases of a central venous catheter positioned on the patient's neck. Continuous ventilation is therefore guaranteed also for intubated patients even if it becomes necessary to re-intervene on the venous access site, since PICC management would take place away from the endotracheal tube, with a low risk of contamination. 

SARS-CoV-2 is a beta coronavirus which structure is composed by a single-stranded positive-sense RNA, an envelope, a nucleocapsid and membrane Spike (S) proteins [39, 40] .

The entry of SARS-CoV-2 into the target cells occurs by means of the viral surface protein "S" that interact with the ACE2 membrane receptor expressed on human cells. A This article is protected by copyright. All rights reserved.

activation. The innate immune response has a rapid implementation, from 4 minutes to 4 hours for the activation of macrophages and of the alternative complement pathway and from 4 hours to 4 days to implement the production of NK cells and the release of IFN.

The activation of the adaptive immunity implies the production of CD8+ specific cytotoxic T-cells and of CD4+ helper T-cells and the activation of specific B cells to produce specific antibodies. After the virus recognition by Toll-like receptor-7 (TLR -7)

in endosomes, TLR -7 activation leads to the production of alpha-interferon, TNF-alpha, and the secretion of interleukin (IL)-12 and IL-6. In some cases, the host greatly amplifies the immune response to attack the virus, which may induce ARDS and a strong involvement of other organs. Thus, the virus is responsible for cell damage through direct and indirect mechanisms. The direct cytopathic damage is due to the viral replication in various parenchyma, mainly in the pulmonary alveoli. Histopathological analysis shows an acute alveolar damage characterized by protein exudate, fibrin deposits, thickening of septa and alveolar walls, hyperplasia of type II pneumocytes and mononuclear inflammatory infiltrate. In clinically severe disease, even other organs (heart, liver and kidneys and the central nervous system) are involved and patients may develop multiorgan failure (MOFS), coagulopathy clinically significant and septic shock.

The indirect damage on target organs acts through a cytotoxic effect on the endothelium with the development of systemic capillary microthrombi and consequent ischemia involving lung, brain, heart, liver, and kidney. The massive release of pro-inflammatory cytokines (Cytokine Release Syndrome-CRS) including various interleukins (IL-2, GM-CSF, IL-6, IL -1, IL-8, TNF-alpha) and chemokines (CXCL9, CXCL10, CXCL1) causes an acute systemic hyperinflammation, probably associated to a secondary hemophagocytic lympho-histiocytosis (sHLH) due to the lack of cytolytic activity of NK or CTL cells that are unable to remove infected cells. This capillary damage may cause This article is protected by copyright. All rights reserved.

life threatening clinical conditions, like an acute Diffuse Alveolar Damage (DAD), which may lead to ARDS and serious heart, brain, liver, and kidney damages, which may progress to MOFS.

In the evolution of COVID-19, in addition to the hyper monocyte-macrophage activation, the patients often experience a serious alteration of the coagulation system which, in the most severe cases, reaches a real diffuse and generalize thrombosis or a massive hemorrhage due to the consumption of fibrinogen. Interestingly, the toxic activity of the poison secreted by the glands of the viper Bathrops jaracara, which study allowed the discovery of ACE inhibitors, has almost superimposable clinical effects thanks to a mixture of peptides capable of potentiating the circulating effects of bradykinin [41] .

of cells more specifically included in the immune system like B, T and NK lymphocytes, histiocytes and antigen-presenting cells. These neoplasms have substantial differences from solid neoplasms. In fact, hematologic malignancies are never confined to an organ because their cells recirculate in the body through the lymphatic system and the blood and can involve organs and tissues. In addition, these transformed cells often retain some functional characteristics they had before their transformation, such as the ability to secrete cytokines and chemokines or to produce immunoglobulins.

In patients with aplasia, bone marrow hypoplasia, invasion of the bone marrow by neoplastic disease and in those with neutropenia, SARS-CoV-2, free to replicate and spread into the body because of the reduced or absent host immune response, causes a direct strong cell damage. SARS-CoV-2 exerts this pathogenetic action in acute leukemias, leukemic lymphomas, aplastic anemia, primitive and congenital neutropenia, This article is protected by copyright. All rights reserved.

all myelodysplastic syndromes with leukopenia, histiocytosis with involvement of the bone marrow and/or hematopoietic organs, paroxysmal nocturnal hemoglobinuria with bone marrow involvement, in patients treated with immunosuppressive therapy or immunochemotherapy, in those who underwent bone marrow transplantation and in those with indolent chronic hematological diseases such as hemolytic anemias, autoimmune thrombocytopenia and aplastic anemia.

In addition, in patients with immune system malignancies causing specific immunological deficits even in the watch and waiting phase, such as chronic lymphoid leukemia B (B-CLL) and multiple myeloma, and in those who have recently practiced or who are taking anti-CD-20 therapies (rituximab, obinutuzumab, etc.) [42] [43] [44] , the reduced antibody response to the virus creates a strong predisposition to bacterial overlaps.

In onco-hematologic diseases involving T lymphocytes, NK, histiocytes and antigenpresenting cells, there is a risk of an immunological hyperactivation induced by SARS-CoV-2, with a high probability of immunopathogenic damage due to a cytokine storm.

However, for each onco-hematologic pathology, it should be considered whether a specific treatment is in progress or has ended recently. In fact, purine analogues leave a lymphocyte T deficiency that may persists for months or years and rituximab causes a deficit in the B-lymphocytes and antibody production, persisting for 9 months or more.

Also patients with multiple myeloma treated with immunomodulatory therapy (lenalidomide, pomalidomide, thalidomide) and patients with chronic myeloproliferative diseases treated with ruxolitinib could have a sort of protection against the risk of activating hyperimmune responses such as a cytokine storm. In addition, the cytokine storm will occur less frequently in patients taking drugs that reduce immunological This article is protected by copyright. All rights reserved. In all cases, it is advisable to practice a diagnostic swab to detect SARS-CoV-2 RNA and if signs or symptoms of influenza like illness (ILI) have occurred, it will be necessary for their resolution and for three consecutive negative swabs. Patients with or without ILI This article is protected by copyright. All rights reserved.

symptomatology but with a history of documented contacts with subjects with SARS-CoV-2 infection or coming from endemic areas should be hospitalized in dedicated areas as if they were SARS-CoV-2 positive; this until the RNA test has resulted steady negative.

Onco-hematologic patients with no history of contact with positive COVID-19 patients and absence of ILI symptoms who need hospitalization will have access to areas of hematology.

The body's first weapons of defense against pathogens' attacks are the natural physical, chemical, and biological barriers. According to some authors, even this first line of defense can be considered as part of the non-adaptive innate immunity that, in this case, would be constituted not only of cells and mediators, but also of tissues that act as a barrier to the penetration of microbes both for their physical structuring and for specific defensive substances they produce or secrete. The epithelium of the upper and lower airways plays an important role. In fact, in addition to trapping the coarser particles through the vibrissae, the nose produces a mucus which contains in addition to water, ions, and mucins, 0.1-0.5% of antimicrobial proteins such as lysozyme, lactoferrin, βdefensin, IgA and IgG. Besides, the airways contain: a) a muco-ciliary scale with a series of cilia, which moves the mucus in the oral direction by filtering its contents; b) surfactants and mucus capable of trapping pathogens from the inspired air; c) defensinsecreting cells.

In addition to these natural defense mechanisms, clinical researchers are making many attempts to identify treatments able to counteract and eliminate the SARS-CoV2

This article is protected by copyright. All rights reserved.

replication, its unfavorable effects on human immune system and the serious alteration of 

under mechanical ventilation (out of the 53) were extubated [61] . This treatment, however, showed a lower efficacy in a recent study performed by Wang and Coworkers on 236 patients with moderate COVID-19, randomized at a 2:1 ratio with placebo, since the time for clinical improvement and the mortality rate at day 28 did not significantly differ between these two groups. In addition, remdesivir did not significantly reduce the SARS-CoV-2 RNA loads in the upper respiratory tract [60] . Several randomized trials are in progress to evaluate the real effectiveness of remdesivir to cure COVID-19

patients.

-the antimalarial drugs chloroquine (CQ) and hydroxychloroquine (HCQ) which have been proven effective in preventing the internalization of SARS-CoV-2 in cell cultures and reported as effective in COVID-19 treatment in a small study [62] . In a retrospective observational study, COVID-19 was more severe in 811 patients receiving HCQ (600 mg twice on 1st day and then 400 mg daily for 5 days) than in 565 COVID-19 patients treated without HCQ [63] , without a significant association between HCQ-treatment and risk of intubation, or death. In addition, the data, from 671 hospitals worldwide distributed in a multinational registry that included 96,032 subjects with SARS-CoV-2 infection, do not show satisfying results [64] . In fact, of these 96,032, 1,868 COVID-19 patients were treated with chloroquine, and 3,783 in association with a macrolide, 3,016 with HCQ, and 6,221 in association with a macrolide, whereas the remaining 81,144 SARS-CoV-2 positive subjects were used as a control group. Chloroquine and hydroxychloroquine administered alone or association with a macrolide were independently associated both with a higher in-hospital mortality rate and with an increased risk of ventricular arrhythmia [64] . These data suggest not to treat COVID-19

with chloroquine or hydroxychloroquine. Chloroquine and hydroxychloroquine has been This article is protected by copyright. All rights reserved.

used only sporadically in Italy during this SARS-CoV-2 pandemic, but the results of single centers did not show enough efficacy to suggest further investigation.

-the neuraminidase inhibitors oseltamivir and zanamivir used against influenza viruses; SARS-CoV-2 do not present neuraminidase or hemagglutinin and therefore their use appears hardly understandable.

-the serine protease inhibitor camostat mesylate that inhibits the host serine protease TMPRSS2 that splits the spikes protein S into two fragments S1 and 2. As mentioned above, S1 is responsible of the binding of SARS-CoV-2 to the ACE2 receptors on the surface of human cells and S2 of the fusion of viral and cellular membranes, a necessary event for virus entry into the human cells.

-the corticosteroids COVID-19 patients with serious pulmonary involvement show characteristics resembling those of ARDS and of other inflammatory lung diseases potentially sensitive to corticosteroids [65] . In addition, a reduced risk of death has been observed in patients with COVID-19 treated with methylprednisolone, especially if in ARDS [66] . However, there is some concerns about the use of corticosteroids in patients with COVID-19. First, most studies have evaluated patients with ARDS from non-viral causes so previous results cannot be automatically translated to ARDS in patients with COVID-19. In this sense, the WHO has recently expressed an opinion against the use of steroids in COVID- 19 if not necessary for other reasons [67] . In addition, the literature shows conflicting data on the use of corticosteroids in SARS and in MERS, due to the significant adverse reactions [68, 69] and it was also observed that patients with SARS treated with hydrocortisone show increased viremia, an unfavorable effect attenuated if low-dose steroids are used [70] . This article is protected by copyright. All rights reserved.

The lack of evidence from randomized trials does not allow to conclude on the use of corticosteroids in COVID19. However, from what it has been observed in Italy during this SARS-CoV-2 pandemic we are allowed to believe that the use of steroids is not recommended in the initial stages of COVID-19 when the disease is directly related to action of the virus, while in cases with serious lung disease and ARDS due to the cytokine storm the administration of methylprednisolone (0.5-1 mg/kg/day for 5-7 days) may be useful. Overall, only a clinical common sense can guide doctors in making a case-by-case decision, pending the results of future randomized trials to define the real usefulness of steroid therapy in COVID-19

Therapeutic attempts to reduce the cytokine storms There is also evidence that alterations in the complement system play a pivotal rule in dysregulating immune mechanisms that lead to ARDS and MOFS in COVID-19. About that, the monoclonal antibody eculizumab has been proposed as a modulator of the distal complement activity. In addition, also same mTOR inhibitors, such as rapamycin and, better, everolimus have been proposed in such a therapeutic setting. Some proteasome inhibitors could be also proposed for their NFκB transcription factors which play a central role in the induction of many cytokines.

In the absence of specific effective drugs, convalescents' plasma has been used to treat or to reduce the aggressiveness of several infectious diseases in the 20th century and to successfully treat -SARS, MERS and H1N1 infections in the first two decades of the third millennium [71] [72] [73] .

Infused intravenously with plasma from convalescent donors containing neutralizing antibodies to SARS-CoV-2, patients with severe COVID-19 have shown significant improvement in small non-randomized studies and randomized trials are now in progress [74] [75] [76] [77] . Noteworthy, the large number of infected patients is fortunately counterbalanced by the large number of convalescent subjects, so there should be no problem of exhaustion of plasma supplies. Plasma administrations is also useful for a faster recovery of virus weakened and undernourished patients.

The extreme rapidity of spreading of the COVID-19 pandemic and the high frequency of severe or fatal forms have prompted numerous authors and pharmaceutical or This article is protected by copyright. All rights reserved.

Studies aimed at developing SARS-CoV-2 vaccines are conducted in several countries with different lines of development. The attempts underway concern vaccines with inactivated or attenuated viruses, vaccines with protein sub-units (mainly with the spike protein S and with the virus like Proteins (VLP) vaccines based on viral vectors, vaccines based on DNA or RNA [89] . It is hoped that some of the vaccines under investigation will have full success, and the results of the first clinical trials bode well. Considering that most of the world population will have to be vaccinated it is foreseeable that all vaccines that prove effective in neutralizing SARS-CoV-2 will be widely used.

This article is protected by copyright. All rights reserved.

This review article could be useful also for infectious disease specialists who for some reason have not had the opportunity to treat COVID-19 patients and for family doctors who can in more than one opportunity visit these patients.

As often happens in situation of extreme emergency, a further contribution to the sense of uncertainty and fear of populations is given by the frequent disagreement among politicians who, instead, should decide together appropriate actions to limit the spread of the virus and ensure adequate support and treatment for citizens. Add to this, the numerous disputes between experts, politicians and journalists worldwide shown in TV talk shows and in other media further feed the general feeling of inadequacy towards the spreading infection.

We believe, however, that we must not let ourselves be discouraged and live in the certainty that humanity will be able to effectively combat this pandemic, as in the past it has done in other catastrophic situations caused by wars, natural disasters or terrible pandemics. This will happen again if everyone will make its contribution in the context of a joint action.

The Novel Coronavirus (SARS-CoV-2) Epidemic

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China

American Society for Transplantation and Cellular Therapy. ASTCT response to

Physical activity in elderly kidney transplant patients with multiple renal arteries

Post Heart Transplantation Lymphoproliferative Diseases (PLTDs) and the diagnostic role of

2019 novel coronavirus infection and gastrointestinal tract

Water, sanitation, hygiene and waste management for COVID-19

Presumed Asymptomatic Carrier Transmission of COVID-19

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

One-stage resection of primary colorectal cancer and hepatic metastases using the habib device: analysis of 40 consecutive cases treated in a unit of general surgery

Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study

This article is protected by copyright. All rights reserved

Evolving status of the 2019 novel coronavirus infection: proposal of conventional serologic assays for disease diagnosis and infection monitoring

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

COVID-19 in a patient with pre-existing acute lymphoblastic leukemia

MicroRNome analysis unravels the molecular basis of SARS infection in bronchoalveolar stem cells

A Preliminary Study for Quantitative Assessment with HFUS (High-Frequency Ultrasound) of Nodular Skin Melanoma Breslow Thickness in Adults Before Surgery: Interdisciplinary Team Experience

CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products

COVID-19 Outbreak: An Overview

COVID-19, ACE2, and the cardiovascular consequences

Use of Rituximab in NHL Malt Type Pregnant in I° Trimester for Two Times

Clinical significance of serum triple monoclonal components: a report of 6 cases and a review of the literature

Serum double monoclonal components and hematological malignancies: only a casual association? Review of 34 cases

Bedside Doppler ultrasound for the assessment of renal perfusion in the ICU: advantages and limitations of the available techniques. Lymphomatoid papulosis

Dermoscopic characterization of folliculotropic mycosis fungoides selectively localized on trunk and limbs

Primary Cutaneous DLBCL Non-GCB Type: Challenges of a Rare Case

Primary cutaneous B cell lymphomas: an update. Front

Extracorporeal photopheresis in elderly patient with refractory Mycosis Fungoides

Bilateral lacrimal gland involvement with mantle cell lymphoma

Contrast-enhanced ultrasound: a new vision of microcirculation in the intensive care unit

HIV-1 recombinant forms in immigrants regularly residing in Milan, northern Italy. Infection

Direct-acting Antivirals in relapsed or refractory Hepatitis C Virus-associated Diffuse Large B-cell Lymphomas

Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas

This article is protected by copyright. All rights reserved

Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis

Absence of occult HCV infection in patients experiencing an immunodepression condition

Absence of occult hepatitis C virus infection in patients under immunosupressive therapy for oncohematological diseases

Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Compassionate Use of Remdesivir for Patients With Severe Covid-19

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

This article is protected by copyright. All rights reserved

Observational Study of Hydroxychloroquine in Hospitalized Patients With Covid-19

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Geneva: World Health Organization

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19

Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma

This article is protected by copyright. All rights reserved

Use of convalescent plasma therapy in SARS patients in Hong Kong

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

The pandemic pipeline

A Review of SARS-CoV-2 and the Ongoing Clinical Trials

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

This article is protected by copyright. All rights reserved

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Gastroenterological complications in kidney transplant patients. Open Medicine

Chronic conventional disease-modifying antirheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient

The role of heparin in sepsis: much more than just an anticoagulant

Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis

Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of randomized controlled trials

Clinical observations of low molecular weight heparin in relieving inflammation in COVID-19 patients: A retrospective cohort study

The Race for Coronavirus Vaccines: A Graphical Guide

SARS-CoV-2 vaccines: status report

This article is protected by copyright. All rights reserved